HK. 1548

GenScript Biotech Corporation

Make People and Nature Healthier through Biotechnology

Disclaimer*

Forward-Looking Statement

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-HKFRS Measures)

We have provided adjusted net profit,, which excludes the share-based compensation expenses are not required by, or presented in accordance with, HKFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-HKFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with HKFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under HKFRS, or as being comparable to results reported or forecasted by other companies.

About GenScript

Company Overview

- Our History
- Global Footprint
- Talents
- Financial Snapshot

Business Segments

- Life Science
- Biologics CDMO
- Industrial Synthetic Biology Products
- Cell Therapy
- Business Strategies

Key Investment Highlights

GenScript Employee Photography

Mission

Make People and Nature Healthier through Biotechnology

2002

Founded in New Jersey, US

2013

Established Bestzyme

(Industrial Synthetic Biology Product Segment)

2014

Founded Legend Biotech

(Cell Therapy Segment)

2015

GenScript was listed on HKEX

(stock code: HK.1548)

2017

Legend Biotech and Janssen entered into global strategic collaboration on cilta-cel

2018

Established Biologics CDMO Segment

(GenScript ProBio)

2020

Legend Biotech was listed on Nasdaq (NASDAQ: LEGN)

Launched GenScript ProBio

2021

Group, ProBio and Legend Biotech received funding of $1 billion from Hillhouse Capital

2022

CARVYKTI® granted approval by US FDA, EC and Japan MHLW

Global Footprint*

- Global Presence
  US, Europe, APAC
- Services
  100+ countries and regions
  200,000+ customers
- 190+ granted patents
  820+ patent applications



*As of June 30, 2022

Talents — Foundation for Long-term Growth

Robust Talent Pool and R&D Team[1]

> 5,500
Global employees

> 800
R&D team

~98%
Employee training coverage

Diverse Workforce[1]

57%
Female employees

40%
Master's degree or higher

17%
Overseas employees[2]

1. As of June 30, 2022
2. Ex-China

Financial Snapshot

Revenue ($M)[1]

FY18 - FY21 Revenue CAGR ~30%



Diversified Revenue Composition[1]



~$1,264M Cash Position[1]

- ✓ Non-cell therapy cash position at $474.5M
- ✓ Cell Therapy cash position at $789.0M

~$305M Revenue[1]

- ✓ Non-cell therapy revenue at ~ $283M
- ✓ Cell Therapy revenue at ~$57M

~1591% ROI since IPO[2]

- ✓ HK$1.31 @ IPO
- ✓ HK$22.15 @ 12/25/2022

1. As of June 30, 2022. Cash Position=Current Financial assets at fair value through profit or loss + Financial investment measured at amortized cost+ Pledged deposits + Time deposits+ Cash and cash equivalents
2. As of December 25, 2022

Business Platforms

GenScript
Make Research Easy

GenScript Life Science Group

GenScript PROBIO

Bestzyme

LEGEND BIOTECH



GenScript Life Science Group – Make Research Easy

The GenScript Life Science Group is the world-leading enabling platform serving the scientific community by providing reliable, high quality and innovative reagents and instruments with superior customer service to enable success across a wide variety of existing and emerging life science research and development areas.





Services and Products Portfolio

Services

Gene Synthesis

- World's largest gene synthesis provider*
- 99.95% success rate, 99% on-time delivery*
- Longest synthetic gene fragment up to 200kb*
- Proprietary GenSmart™, VectroArk™ and CloneArk™ for synthesis

Oligo Synthesis and CRISPR

- >18 years of experience in oligo synthesis
- ISO9001 and ISO13485 certified cleanrooms and sgRNA for IND filing and IVD product IND filing
- Chemical modification of nucleotides supports various applications

Peptide Synthesis

- >17 years of experience in peptide synthesis
- Solid and liquid phase peptide synthesis and microwave technologies with 98% one-time success rate*
- Multi-channel large-scale synthesis up to kg level

Protein Production

- >18 years of experience in protein synthesis with purity up to 98%*
- TurboCHO™ high-throughput system delivers high-quality, challenging proteins
- Gene synthesis to proteins or antibodies in just 6 days

Antibody Development

- >18 years of experience with 150,000 projects delivered
- MonoRab™ B cell cloning platform for rapid development of diverse antibodies in just 11 weeks
- OLAW and AAALAC certified animal facilities

Products

Reagents and Instruments

- Total solutions for protein electrophoresis and blotting
- Stable cell line
- IVD antibodies, antibody products
- Protein Purification

Gene and Cell Therapy

- CytoSinct™ cell separation solution
- AmMag™ Quatro automated solution for plasmid purification
- GenCRISPR™/Cas9 gene editing tool

*As of June 2022

Innovation Drives Long-term Sustainable Growth

- Empowered by HTP gene synthesis platform and proprietary TurboCHO™ transient expression technology
- As fast as 10 days from sequence to purified product
- Wide range of purified antibody products (e.g., IgGs, Fab, scFv, VHH, bi-specific antibodies, and more) in quantities (from ug to mg)

- For precision gene editing, higher efficiency, lower immunogenicity, and larger payload content (up to 50kb)
- 8 patent filings for new products and production process protection
- Complete manufacture capability from RUO to GMP

- Out-of-the-Box Solution
- Purify up to 24 samples with a 4-module setup in 2 hours
- Modular design provides throughput scalability with individual module operation, with each module purifying up to 6 samples
- High yield, low endotoxin, transfection grade plasmid DNA

- Complete Solution: Instrument, Protocols and Consumables
- Easy Operation: Guided tube installation, and intuitive touchscreen interface with an integrated barcode scanner
- Enclosed Solution: Sterile operation with a closed system
- High Quality: Excellent cell recovery, purity, viability and activation

Life Science Group Capacity Expansion

Phase I 2022 | Phase II 2023 | Phase III 2024

Zhenjiang Life Science Building ~**397,940 ft²** Modular Construction

2020	2021	2022	2023	2024
Seattle Innovation Center **27,986 ft²**	Singapore Protein Lab & Logistic Center **18,191 ft²**	Singapore MB Lab (Pilot Now) **11,625 ft²**	 Zhenjiang Molecular Building **213,986 ft²**	 Nanjing Life Science Building **205,375 ft²**
Piscataway MB Lab **55,972 ft²**	Zhenjiang Plasmid Lab **64,475 ft²**	Nanjing Life Science Services and Instruments **66,090 ft²**		
Nanjing Park **253,382 ft²**	Shanghai Virus/ Cell Line Lab & Logistic Center **14,961 ft²**	Piscataway MB Lab **55,972 ft²**		
Zhenjiang Park **145,851 ft²**				

GenScript ProBio — Innovation through Collaboration

With a one-stop biologics R&D and manufacturing platform, GenScript ProBio is committed to providing end-to-end CDMO services from target development to commercial manufacturing for GCT drugs, vaccines, biologics discovery, and protein and antibody drugs.



One-stop End-to-end CDMO Services

Gene and Cell Therapy

Discovery

- Antibody Discovery for mRNA Therapy
- CAR Candidate Molecule Discovery
- State-of-the-Art ProSpeed™ Single B Cell Platform
- Fully Human Ab Discovery
- SMAB Bispecific Antibody Platform

Pre-clinical/ Development

- Plasmid, Virus, mRNA CMC
- Plasmid, Virus, mRNA manufacturing for preclinical research
- Fed-batch, intensified fed-batch, perfusion process development
- Proprietary Cell Line Development Platform

Early Stage Clinical

- GMP Plasmid Manufacturing
- GMP Virus Manufacturing
- GMP mRNA Manufacturing
- Clinical Manufacturing

Late Stage Clinical/ Commercialization

- GMP Plasmid Manufacturing for Commercial Use
- IN PLANNING: GMP Virus, mRNA Manufacturing for Commercial Use
- Process Characterization, Process Validation
- Commercial Manufacturing

Biologics

Cutting-edge Platforms

Biologics

Fully Human Antibody Discovery

- ✓ 3 transgenic animal platforms
- ✓ As fast as 1 month to get fully human antibody sequence

Single B Cell Screening Platform

- ✓ Highly efficient, automated and comprehensive
- ✓ Expedited timeline to 1.5 months with mAb production

ProCLD Cell Line Development

- ✓ Host cell CHOK1-GenS
- ✓ Full history and traceability documentation, IP clear
- ✓ High productivity up to 8.7g/L, excellent stability in 60-90 generations

SMABody® Bispecific Antibody Platform

- ✓ Most natural bispecific antibody platform
- ✓ No sequence mutation
- ✓ Robust screening and engineering



Bispecific Antibody and Protein CMC

- DNA to Tox batch in 7 months for symmetric BsAb, 8 months for asymmetric BsAb
- Cell line, process and analytics toolkit to address mispairing and low expression
- Proprietary bioassay platform for customized bioassay design and construct
- High-density seeding, supernatant expression increased by 80%-150% in cell culture process validation

Optimized Process Development and Manufacturing Capacity

Perfusion Process Development

- Up to 80g/L titer, >10x higher productivity
- 6 months from DNA to Tox

GMP Clinical Manufacturing

- 5 independent large-scale cell culture GMP upstream production lines
- 3 independent downstream purification production lines
- Tech Transfer in only 2 months
- Comply with NMPA, FDA, EMA regulations

*As of Dec 2022

Leading Gene and Cell Therapy CDMO

Lentiviral Vector Platform

- Ready-to-use LentiBone™ with clear IP and traceability
- Reliable LVV Suspension System: superior yield, cost effective, high T cell transduction efficiency
- Enclosed upstream process for LVV Adherent System

AAV Vector Platform

- Proprietary Cell Line PowerS™-293: superior monoclonal dispersion, higher cell density and viability, shorter cell doubling time
- High titer performance in different AAV serotypes：3E13-1E14 vg/L

One-stop Plasmid CDMO for Various Applications

- Various applications: CAR-T, TCR-T, UCART, CAR-NK, CRISPR, gene therapy, mRNA vaccine, DNA vaccine/DNA drug or LcDNA
- One-stop solution: CMC (IND filing), GMPro (clinical mfg.) to GMP (commercial mfg.)
- Clear IP and traceability of strain and ready-to-use LVV helper plasmids

One-stop mRNA Service

- Plasmid + IVT-mRNA + mRNA-LNP integrated solutions
- IVT-mRNA：Enzymatic & co-transcriptional capping (License in)
- mRNA-LNP: suitable for different LNP formulas, encapsulation efficiency up to 99.7%, excellent CQA characterization
- Comprehensive, in-house mRNA analysis platform: compliant with GMP requirements in China, US & Europe, multiple analysis methods to characterize mRNA

Solid Track Record

From Discovery to Clinical*

Biologics

- 13 Global License-out projects
- 82+ CMC & CMO projects
- 20+ IND approvals from NMPA and FDA: mAb, ADC, recombinant protein
- 103+ GMP batches completed

1,430+	Multiple Discovery Platforms	
82+	Preclinical Development	*60+*
103+	Clinical	*200+*

GCT

- 60+ Global CMC projects
- 24 IND approvals from NMPA, FDA,PMDA, MFDS : CAR-T, TCR-T, mRNA vaccine and CRISPR related cell therapy
- 200+ Global Clinical mfg. batches

*As of Dec. 2022

CDMO Capacity Expansion

Biologics

-2023 **Nanjing**

10,333 ft² Antibody Discovery & Pharmacology Lab

-2023 **Zhenjiang**

72,118 ft² Antibody Process Development

8*2,000 L Biologics Commercial Manufacturing Center

Gene and Cell Therapy

-2023 **Zhenjiang**

72,118 ft² Plasmid cGMP Facility

72,118 ft² Virus cGMP Facility

-2024 **Zhenjiang**

365,972 ft² Plasmid, mRNA, Virus cGMP & QC Facility

-2024 **New Jersey***

113,021 ft² Plasmid GMP Facility

*59,201 ft² will be ready by 2024

Bestzyme - Make the Best Enzyme

Leveraging independent R&D capabilities in synthetic biology, Bestzyme offers a wide range of enzyme products which can be applied in various industries such as feed, bio-ethanol, starch, textile and food.




Create a Better World through Enzyme Innovation

Advanced R&D Platform

- ✓ >80 R&D staff*
- ✓ ~55+ granted patents, ~45+ patents applications

State-of-the-Art Technology

- ✓ >6 industrial bacterial and fungal expression platforms
- ✓ Industry-leading enzyme molecule discovery and screening platform
- ✓ End-to-end delivery capability

Market-oriented Business

- ✓ Automated production capacity of industrial enzyme >150,000 metric tons
- ✓ Integrated enzyme solutions provider
- ✓ Strategic partnerships with key accounts

*As of Dec 2022

R&D Driven DNA to Commercial Enzymes



Comprehensive Product Portfolio & Production Capability

- ✓ 150,000 metric tons annual production capacity
- ✓ Fully automated production line



One-key fermentation control system

Spray tower

Membrane filtration system

Automatic packing system

Industrial Enzyme	Alcohol: SuperLIQ, HighDEX A, AlcGEN P Series Baking: BestBAKER Series Home Care: PuriWise Series Starch Sugar: SuperLIQ, LiqFINE,HighDEX, Dexfree Series Textile: SuperLIQ TEX, Cata TEX
Compound Enzyme	ProMax: protease, phytase, energy enzyme, intestinal health enzyme, raw material pretreatment enzyme
Feed Enzyme	Single enzyme: keratinase, amylase, NSP enzyme, lipase, cellulase, acid/neutral/alkaline protease, glucose oxidase, xylanase, mannanase, a-galactosidase
Synthetic Biology	Functional protein: health and nutrition, better sensory experience, and low-carbon emission production solutions

Legend Biotech - Pursuit of a Cure

Legend Biotech is a global biopharmaceutical company dedicated to R&D, clinical, production and commercial development of cell immunotherapies for the treatment of tumors. Legend Biotech is among top-tier cell therapy companies.

Multiple Myeloma: Blood Cancer with a High Unmet Need

3RD MOST COMMON BLOOD CANCER

accounting for **18%** of all hematologic cancers[1-3]

176,404

NEW CASES WORLDWIDE IN 2020,

accounting for 1% of worldwide new cancer cases [3, 4]

US: Incidence is

32,119,

with mortality of 13,426[5]

EUROPE: Incidence is

50,918,

with mortality of 32,495[6]

CHINA: Incidence is

21,116,

with mortality of 16,182[5]

POOR SURVIVAL OUTCOMES IN MULTIPLE REFRACTORY MM

Median OS < 12 months

in patients refractory to anti-CD38, ≥ 1 PI(s) and/or ≥ 1 IMiD(s)[8]



Median OS for each group

	Median OS (months)	95% CI
Non-triple-refractory	11.2	(5.4–17.1)
Triple-and quad-refractory	9.2	(7.1–11.2)
Penta-refractory	5.6	(3.5–7.8)

CI, confidence interval; PI, Proteasome Inhibitor; IMiD, immunomodulatory drug; MM, multiple myeloma; OS, overall survival

Cancer Stat Facts: Myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed June 2021. 2. Facts and Statistics. https://www.lls.org/facts-and-statistics/facts-and-statistics-overview. Accessed June 2021. 3. Globocan 2020 World Fact Sheet: https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf. Accessed June 2021. 4. Globocan 2020 World Fact Sheet: World. https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed June 2021. 5. Globocan 2020 World Fact Sheet: United States of America. http://gco.iarc.fr/today/data/factsheets/populations/840-united-states-of-america-fact-sheets.pdf. Accessed June 2021. 6. Globocan 2020 World Fact Sheet: Europe. https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf. Accessed June 2021. 7. Globocan 2020 World Fact Sheet: China. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf. Accessed June 2021. 8. Gandhi UH, et al. Leukemia. 2019;33:2266-75.

This presentation is for investor relations purposes only – Not for product promotional purposes

Global Clinical Program for Cilta-cel

Late Line Studies of Therapy

	NCT03548207
CARTITUDE-1[1]	• Phase 1b/2, multi-center registrational study of cilta-cel in RRMM • Fully enrolled and ongoing in US and Japan

	NCT03758417
CARTIFAN-1[2]	• Phase II, multi-center registrational, confirmatory study of cilta-cel in RRMM • Ongoing in China

	NCT03090659
LEGEND-2[3]	• Phase 1, multi-center study of LCAR-B38M CAR-T cells in RRMM • Fully enrolled and ongoing in China

Earlier Lines of Therapy

	NCT04133636
CARTITUDE-2[4]	• Global, multi-cohort study • Phase II open-label study of cilta-cel in various clinical settings • Enrolling

	NCT04181827
CARTITUDE-4[5]	• Global, randomized, registrational study • Phase III open-label study of cilta-cel vs DPd or PVd in patients with RRMM, 1–3 lines of prior therapy and refractory to lenalidomide • Enrollment completed

	NCT04923893
CARTITUDE-5[6]	• Global, randomized, registrational study • Phase III open-label study of VRd followed by cilta-cel vs. VRd followed by Rd maintenance, in patients with NDMM for whom ASCT is not planned as initial therapy • Enrolling

	NCT05257083
CARTITUDE-6[7]	• Global, randomized, registrational study • Phase III open-label study comparing DVRd followed by cilta-cel vs. DVRd followed by ASCT in NDMM patients who are transplant eligible • Not yet enrolling

ASCT, autologous stem cell transplant; DPd, daratumumab, pomalidomide, dexamethasone; DVRd, daratumumab, bortezomib, lenalidomide, dexamethasone; EU, European Union; JP, Japan; NDMM, newly diagnosed multiple myeloma; PVd, pomalidomide, bortezomib, dexamethasone; RRMM, relapsed and/or refractory multiple myeloma; SoC, standard of care; US, United States; VRd, bortezomib, lenalidomide, dexamethasone.

[1] NCT03548207. Clinicaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT03548207; [2] NCT03758417. Clinicaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT03758417. CARTIFAN-1 is registration study for China only; [3] NCT03090659. Clinicaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT03090659. [4] NCT04133636. Clinicaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT04133636. [5] NCT04181827. Clinicaltrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04181827. [6] NCT04923893. Clinicaltrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04923893. [7] NCT05257083. Clinicaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT05257083. CARTITUDE-6 is a collaborative study sponsored by the European Myeloma Network.

Global Approval of Cilta-cel in the US, EU and Japan

Consistent efficacy results across 3 datasets with a manageable safety profile

CARTITUDE-1[1] (N=97)

98% ORR 83% sCR

mPFS Not Reached at 27.7 mo follow-up

≥3 prior therapies or double refractory, Prior PI, IMiD, anti-CD38 antibody exposure

CARTITUDE-2

Cohort A[2](N=20)

95% ORR 90% SCR/CR

mPFS Not Reached at 17.1 mo follow-up

Progressive MM After 1–3 Prior Lines of Therapy and Lenalidomide Refractory

Ongoing Ph 3

CARTITUDE-4

After 1–3 Prior Lines of Therapy and Lenalidomide Refractory

CARTITUDE-2

Cohort B[3] (N=19)

100% ORR 90% sCR/CR

mPFS Not Reached at 18 mo follow-up

Early relapse after front-line therapy including PI, IMiD or ASCT

CARVYKTI® (cilta-cel) Commercial Approvals

Approved by the US FDA on February 28, 2022	FDA U.S. FOOD & DRUG ADMINISTRATION
Conditional Approval by the EC on May 26, 2022	EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH
Approved by Japan MHLW on September 26, 2022	ひと、くらし、みらいのために 厚生労働省 Ministry of Health, Labour and Welfare

1. Usmani et al. ASCO Annual Meeting; June 3-7, 2022; Chicago, Il & Virtual; Abstract #8028; 2. Einsele et al. ASCO Annual Meeting; June 3-7, 2022; Chicago, Il & Virtual; Abstract #8020; 3. Van de Donk et al. ASH Annual Meeting & Exposition; Dec 10-13, 2022; New Orleans, LA; Abstract #3354

Global Manufacturing Footprint

US Facilities

BCMA US / EU / JP / ROW
Launch/ Commercial Site

US / EU / JP Legend Clinical Supply Site

EU Facilities

Future Commercial Site

Future Commercial Site

China Facilities

BCMA China Launch Site & Legend Clinical Supply Site

Future Commercial Site

Robust Pipeline

Pre-clinical

- **NSCLC (GPC3)** — Autologous
- **GASTRIC & ESOPHAGEAL‡ (CLAUDIN 18.2)** — Autologous
- **COLORECTAL (GCC)** — Autologous
- **SCLC‡ (DLL3)** — Autologous
- **AML (CLL1/CD33)** — Allogeneic

Phase I

- **NHL† /ALL† (CD19 X CD20 X CD22)†** — Autologous; NCT05318963; NCT05292898
- **RRMM (BCMA) LEGEND-2†** — Autologous; NCT03090659
- **GASTRIC, ESOPHAGEAL & PANCREATIC† (CLAUDIN 18.2)** — Autologous; NCT04467853
- **HCC† (GPC3)** — Autologous; NCT05352542
- **MM† (BCMA)** — Allogeneic – CAR-NK; NCT05498545
- **MM† (BCMA)** — Allogeneic – CAR-γδ T; NCT05376345

Phase II

- **RRMM (BCMA)* CARTIFAN-1** — Autologous; NCT03758417
- **RRMM (BCMA)* CARTITUDE-1** — Autologous; NCT03548207
- **MM (BCMA)* CARTITUDE-2** — Autologous; NCT04133636

Phase III

- **RRMM (BCMA)* 1-3 Prior Lines CARTITUDE-4** — Autologous; NCT04181827
- **NDMM (BCMA)* Transplant Not Intended CARTITUDE-5** — Autologous; NCT04923893
- **NDMM (BCMA)* Transplant Eligible CARTITUDE-6** — Autologous; NCT05257083

Global | China | US

*In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson.
†Phase 1 IIT in China.
‡Multiple allogeneic platforms are being developed.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCMA, B-cell maturation antigen; DLL3, delta-like ligand 3; GPC3, glypican-3; GCC, guanylyl cyclase C; HCC, hepatocellular carcinoma; IIT, investigator-initiated trial; MM, multiple myeloma; ND, newly diagnosed; NHL, non-Hodgkin lymphoma; NSCLC, non small cell lung cancer; RRMM, relapsed or refractory multiple myeloma; SCLC, small cell lung cancer.

Business Strategies

GenScript Life Science Group

- Increase R&D to enable GCT service & product
- Upgrade technology platforms: automation & high throughput
- Improve global capacity operation

GenScript PROBIO

- Expand our target customer segments to seek high quality business growth
- Build solid international business and scale up GMP capacity
- Become a leading GCT CDMO

Bestzyme

- Enhance tech transfer from R&D to industrial-grade manufacturing
- Optimize product portfolio
- Increase international market penetration

LEGEND BIOTECH

- Improve cilta-cel production capacity to support commercialization
- Speed up early line clinical trials for cilta-cel
- Advance pipeline programs in liquid and solid tumors

Key Investment Highlights

1. Life Science Group: Sustainable revenue growth with solid profitability
2. GenScript ProBio: Strong revenue growth with upside potential
3. Bestzyme: Improved profitability and synthetic biology market opportunities
4. Legend Biotech: Unlock CARVYKTI® potential and advance other pipelines
5. Strong synergies across four segments

HK. 1548

GenScript Biotech Corporation

Make People and Nature Healthier through Biotechnology

Thanks

For More Information: https://www.genscript.com/